Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
- Conditions
- Myelodysplastic SyndromesLeukemia, Myeloid, Acute
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 6990
- Registration Number
- NCT06956755
- Locations
- 🇫🇷
Aspasia Stamatoullas, Rouen, France
Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
- Conditions
- Low-risk Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 24
- Registration Number
- NCT06670222
- Locations
- 🇫🇷
CHU de Nice - Hôpital l'Archet - Service d'hématologie clinique, Nice, France
🇫🇷Hôpital Saint Louis - Service Hématologie séniors, Paris, France
🇫🇷Institut Gustave Roussy - Service d'hématologie, Villejuif, France
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 36
- Registration Number
- NCT05782127
- Locations
- 🇫🇷
CH Valence, Valence, France
🇫🇷Hôpital privé Sévigné, Cesson Sévigné, France
🇫🇷CHU d'Amiens Picardie - Site sud, Amiens, France
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 44
- Registration Number
- NCT05768711
- Locations
- 🇫🇷
Hôpital Claude Huriez, Lille, France
🇫🇷Hôpital NOVO, Pontoise, France
🇫🇷CHU d'Amiens, Amiens, France
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
- Conditions
- AMLMDS
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 55
- Registration Number
- NCT05226455
- Locations
- 🇫🇷
CHU d'Amiens Picardie - Site sud, Amiens, France
🇫🇷CHU d'Angers, Angers, France
🇫🇷CHU de Grenoble, Grenoble, France
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
- Conditions
- MDSMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 150
- Registration Number
- NCT05181735
- Locations
- 🇫🇷
Clinique de l'Europe, Amiens, France
🇫🇷Hôpital privé du Confluent, Nantes, France
🇫🇷Centre Hospitalier de Versailles, Le Chesnay, France
ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 57
- Registration Number
- NCT04857645
- Locations
- 🇫🇷
CHU d'Angers - Service des maladies du sang, Angers, France
🇫🇷CHU de Grenoble - Clinique Universitaire d'hématologie, Grenoble, France
🇫🇷CHU d'Amiens Picardie - Site sud - Service hématologie clinique et thérapie cellulaire, Amiens, France
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 38
- Registration Number
- NCT04827719
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇫🇷CHU de Bordeaux Haut-Lévèque, Bordeaux, France
🇫🇷CHU Amiens, Amiens, France
CPX-351 in Higher Risk Myelodysplastic Syndromes
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Drug: CPX-351 in cohort ADrug: CPX-351 in cohort B
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 40
- Registration Number
- NCT04273802
- Locations
- 🇫🇷
CHU d'Amiens - Service d'hématologie clinique et thérapie cellulaire, Amiens, France
🇫🇷Centre hospitalier Victor Dupouy - Service d'Hématologie, Argenteuil, France
🇫🇷CHU d'Angers - Service des maladies du sang, Angers, France
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
- Conditions
- Leukemia Acute MyeloidMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 68
- Registration Number
- NCT03744390
- Locations
- 🇫🇷
CHU de Bordeaux, Bordeaux, France
🇫🇷Hôpital Henri Mondor, Créteil, France
🇫🇷Hôpital André Mignot, Versailles, Le Chesnay, France